Next-Generation Regenerative Therapy for Wound Healing
Technology No. BRA08-01
Palatable Bowel Preparation for Improved Colonoscopies
Technology No. POC01-03
Self-Assembling Protein Fibers and Hydrogels as Theranostic Agents
Technology No. MON02-15.19
FINO2 Compound for Ferroptosis (150 mg)
Technology No. WOE01-04
OT-II LAG-3-/- mouse
Technology No. WAN05-21
OT-I LAG-3-/- mouse
Technology No. WAN05-20
RAGE conditional knockout transgenic mice (Columbia)
Technology No. SCH08-11
AGER Conditional Knockout Transgenic Mice (Columbia)
Technology No. SCH08-10
Diaph1 conditional knockout transgenic mice (Columbia)
Technology No. SCH08-09
Engineered murine fallopian tube epithial cell line that contains rp53 -/-; Brca1 -/-; MycOE
Technology No. NEE02-11
Engineered murine fallopian tube epithial cell line that contains rp53 -/-; Ccne1OE; MycOE
Technology No. NEE02-10
B6.Cg-Ptprca Cx3cr1tm1Litt/LittJ (Jax No. 008451) Transgenic mice (HHMI)
Technology No. LIT01-61
GHOST (3) CXCR4+CCR5+ cell line (NIH AIDS Reagent Program Catalog Number: 3942) (HHMI)
Technology No. LIT01-60
B6.129P2-Runx1tm1Tani/J transgenic mice (HHMI) (Jax No. 008772)
Technology No. LIT01-58
C57BL/6-Tg(Tcra,Tcrb)2Litt/J transgenic mice (HHMI) (Jax. No. 027230)
Technology No. LIT01-57
DC-SIGN transgenic mice (HHMI)
Technology No. LIT01-53
B6.FVB-Tg(Rorc-cre)1Litt/J transgenic mice (Jax. No 022791) (HHMI)
Technology No. LIT01-41
C57BL/6-Tg(Cd8a-cre)1ltan/J transgenic mice (Jax No. 008766) (HHMI)
Technology No. LIT01-38
Humanized mouse line expressing the human WT or CX3CR1I249/ M280 polymorphic variant (HHMI/USTA)
Technology No. LIT01-29
C.129P2-Cxcr6tm1Litt/J transgenic mice (HHMI) (Jax No. 005700)
Technology No. LIT01-10
B6.129P2-Cxcr4tm2Yzo/J transgenic mice (HHMI) (Jax No. 008767)
Technology No. LIT01-09
Plasmid SV-Ψ-MLV-env- (BEI catalog # 3422)
Technology No. LAN02-07
SERPINB2 deficient cell lines for enhanced AdV manufacturing purposes
Technology No. DIT01-03
Axsl1 fl/fl:Tet2 fl/fl Conditional Knockout Mice
Technology No. AIF01-23
Susd6 fl/fl Conditional Knockout Mice
Technology No. AIF01-22
Clpb fl/fl Conditional Knockout Mice
Technology No. AIF01-21
C57BL/6 (Rosa-rtTA shTet3)
Technology No. AIF01-19
C57BL/6 (Rosa-rtTA shTet2)
Technology No. AIF01-18
C57BL/6 (Rosa-rtTA shTet1)
Technology No. AIF01-17
Conditional AsxL1 Knock-out Mouse Model (Jax No. 025665)(MSKCC)
Technology No. AIF01-16
iCADD: Next-generation Screening Platform for Identifying Small Molecular Glue Degraders
Technology No. PAG01-16
Novel Screening Platform to Identify Confirmation-Specific SHP2 Inhibitors
Technology No. NEE02-12
Tumor-Targeting Nanoparticles for Precision Chemotherapy in Cancer
Technology No. TRA02-06
Inhibitory Peptides That Selectively Antagonize Neuropilin 1 (NRP1) for Precise Pain Treatment
Technology No. BUN01-02
Peptidomimetic Modulator of CaV2.2 N-type Calcium Channel for Treatment of Chronic Pain
Technology No. KHA03-01
In Silico, Machine Learning-Based Platform to Identify Disease-Causing Senescent Cells
Technology No. WOS01-01
Prognostic Tool for Risk Stratifying Patients with Epilepsy to Improve Clinical Outcomes
Technology No. SAX02-03
CX3CR-1GFP transgenic mice (B6.129P2(Cg)-Cx3cr1tm1Litt/J; Jax stock number: 005582)
Technology No. LIT01-37
Platform for Locally Assembling Antibody Drug Conjugates (ADCs) With Enhanced Specificity
Technology No. NEE02-08
Bright and Photostable Cyanine Dye Tags for Research Applications
Technology No. SAU02-01
Colonic Irrigation Solution
Technology No. POC01-01
Cysteine Depletion as a Treatment for Obesity and Associated Metabolic Disorders
Technology No. LIT01-56
Repurposing Farnesyl Transferase Inhibitors for the Treatment of Cerebral Malaria
Technology No. ROD01-17
Apoptosis Inhibitor 5 (API5)-based Therapeutic for the Treatment of Inflammatory Bowel Diseases
Technology No. CAD01-05
Selective KRAS(G12D)-Binding Monobodies for the Treatment of Cancer
Technology No. KOI01-07
Selective NRAS-Binding Monobodies for the Treatment of Cancer
Technology No. KOI01-10
Catalysts to Efficiently Convert Lignin Biomass to Valuable and Sustainable Chemicals
Technology No. DIA01-01
Multivalent Assembled Proteins (MAPs): Therapeutics for Cancer and Infectious Diseases
Technology No. MON02-11
Chip-based Prognostic Tool for Improved Leukemia Treatment Outcomes
Technology No. CHE11-02
Drug Targets for Overcoming Resistance to KRAS G12C Inhibitors (G12Cis) in Cancer
Technology No. NEE02-05
Novel Probiotic Compositions for Improving Metabolism and Immunity
Technology No. BLA02-12
Therapeutic Hyaluronic Acid and Peptide Composition for Regenerative Repair of Cartilage Injury
Technology No. COW02-02
Injectable Therapeutic Hydrogel for the Treatment of Post-Traumatic Osteoarthritis
Technology No. LIU02-02, MON02-04
Biomarkers of Severe and Cerebral Malaria
Technology No. ROD01-18
Salt-Inducible Kinase Activators to Treat Bone and Mineral Diseases
Technology No. PAR07-01
Small Molecule Inhibitors of SPNS2 for the Treatment of Chronic Inflammatory Diseases
Technology No. SCH14-01
Apolipoprotein B Peptide Mimics for Atherosclerosis Treatment
Technology No. GOL05-04
Efficient and High-Throughput Tool to Engineer Aligned 3D Collagen Matrices for Tissue Culture
Technology No. TEO01-01
Targeting Endocytosis in Nociceptors as a Non-Opioid Treatment Strategy for Chronic Pain
Technology No. BUN01-01
IL-17 Receptor Modulator Screen
Technology No. LIT01-52
Vectored ACE2 Receptor Decoy for Prevention and Treatment of Pan-Coronavirus Infections
Technology No. LAN02-06
Nanobodies Targeting SARS-CoV-2 NSP9 for COVID Treatment
Technology No. PER03-04
Saliva-Based Cytokine Score to Predict the Severity of Clinical Periodontal Inflammation
Technology No. KAM01-01
![CD11c-DTR Transgenic Mice (B6.FVB-1700016L21RikTg [Itgax-DTR/EGFP] 57Lan/J; Jax stock number: 004509 )](https://storage.googleapis.com/elucid3-storage-1-us/uw/product/9154/2/cd11c-dtr-transgenic-mice-b6fvb-1700016l21riktg-itgax-dtregfp-57lanj-jax-stock-number-004509--01.jpg?mtime=20240110144423)
TET2 Conditional Knockout Transgenic Mice
Technology No. AIF01-14
iScore: A Novel Method for Improved Risk Stratification of AML Patients
Technology No. AIF01-12
Targeting the SARS-CoV-2 Viral-Immune Interaction for COVID-19 Therapy
Technology No. WAN05-01
Viral Vector Expression of Gabrb1b for the Treatment of Perceptual Deficits
Technology No. SAN06-01
Targeting a Novel Metabolic Network for Pancreatic Ductal Adenocarcinoma (PDAC) Treatment
Technology No. KIM06-01
Paper-Based, Multiplexed Lamp Diagnostic for Pathogen Detection
Technology No. QAS01-09
Engineered Progranulin: A Promising Therapeutic Approach for Autoimmune Diseases
Technology No. LIU02-03
PHOTACS: Photo-Activatable PROTACS
Technology No. TRA03-01
Multivalent Steroid Conjugates for Treatment of Castration-Resistant Prostate Cancer (CRPC)
Technology No. KIR01-10
Netrin-1 and UNC5B as Novel Targets in Metabolic Liver Diseases: NAFLD & NASH
Technology No. MOO02-06
FGF23 Ligand Trap: New Biologic for Treating Kidney Diseases
Technology No. MOH01-02
Chimeric FGF21: Treatment of NAFLD, NASH and Hepatic Steatosis
Technology No. MOH01-03
Adhesive Bandage for Rapid Pathogen Immune Response Detection
Technology No. QAS01-09
Angiotensin-Converting Enzyme 2 (ACE2) Immunoadhesin Microbody
Technology No. LAN02-03
Nano Zeolite-Y: A Novel and Cost-Effective Antibacterial Composition
Technology No. ANI01-01
ASOs Targeting CHROMR for the Treatment of Inflammatory Diseases
Technology No. MOO02-07
PKP2cKO Transgenic Mouse Model
Technology No. DEL05-01
Anti-CD99 Antibodies Cytotoxic to Leukemia
Technology No. KOI01-05
Oral Insulin Delivery Nanoparticles for Diabetes Treatment
Technology No. TRA02-04
Photoactivatable Lipid Nanoparticles for Drug Delivery
Technology No. TRA03-04
TET2 Modulators for the Treatment of Cancer and Inflammatory Diseases
Technology No. AIF01-09
Succinate Receptor 1 (SUCNR1) Antagonists to Treat Neuroinflammation
Technology No. LI06-03
Avobenzone-Dendrimer Conjugates
Technology No. WEC01-04
NSP14/10 Complex Inhibitors for the Treatment of SARS-CoV-2 and Pan-Coronavirus Infections
Technology No. PAG01-15
